LY2875358

BIOLOGICAL5 trials

Sponsors

Eli Lilly & Co., Eli Lilly and Company

Conditions

Advanced CancerCarcinoma, Non-Small-Cell LungGastric CancerLymphomaNon-Small Cell Lung CancerSolid Tumors

Phase 1

A Study of LY2875358 in Participants With Advanced Cancer

CompletedNCT01287546

Eli Lilly and CompanyAdvanced Cancer

Start: 2010-04-13End: 2016-10-26Target: 117Updated: 2017-02-15

A Study of LY2875358 in Japanese Participants With Advanced Cancer

CompletedNCT01602289

Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung, Lymphoma, Solid Tumors

Start: 2012-06-30End: 2014-08-31Updated: 2015-06-08

Phase 2

A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer

CompletedNCT01874938

Eli Lilly and CompanyGastric Cancer

Start: 2013-08-31End: 2014-12-31Updated: 2015-01-16

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

CompletedNCT01897480

Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung

Start: 2013-08-28End: 2026-01-08Updated: 2026-01-26

I4C-MC-JTBB: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic NSLC Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib

CompletedCTIS2024-514268-18-00

Eli Lilly & Co.Non-Small Cell Lung Cancer

Start: 2013-09-06End: 2026-01-08Target: 2Updated: 2025-12-15

Related Papers

Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models

Cancer Research2017-07-012 citations

A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for <i>EGFR</i>mt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib.

Journal of Clinical Oncology2017-05-2010 citations